All 2010 Releases
 |
Omeros Secures $40 Million Committed Equity Financing Facility
Jul 29, 2010
|
10.8 KB |
|
| |
SEATTLE, July 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd. (the "investor") over a 24-month period. Omeros is not obligated to use the fa...
|
|
Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
Jul 27, 2010
|
11.6 KB |
|
| |
SEATTLE, July 27, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it has enrolled the first patient in its Phase 2b clinical trial eva...
|
|
Omeros Successfully Unlocks Orphan GPCRs
Jun 29, 2010
|
11.9 KB |
|
| |
SEATTLE, June 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has successfully identified compounds that interact with three orphan G protein-coupled receptors (GPCRs) linked to cancer, metabolic disorders and appetite control. This breakthrough demonstrates Omeros' unique capability to in...
|
|
Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
Jun 3, 2010
|
8.0 KB |
|
| |
SEATTLE, June 3, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer of O...
|
|
Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
May 13, 2010
|
11.5 KB |
|
| |
SEATTLE, May 13, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company, today announced that, based on successful preclinical studies, the Company has selected a clinical candidate for its MASP-2 antibody program and has initiated the cGMP manufacturing development process in prep...
|
|
Omeros Reports First Quarter 2010 Financial Results
May 12, 2010
|
11.9 KB |
|
| |
SEATTLE, May 12, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the first quarter ended March 31, 2010.
Total opera...
|
|
Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
May 3, 2010
|
12.7 KB |
|
| |
SEATTLE, May 3, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical b...
|
|
Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
Apr 29, 2010
|
8.0 KB |
|
| |
SEATTLE, April 29, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer of...
|
|
Omeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results
Mar 31, 2010
|
17.1 KB |
|
| |
SEATTLE, March 31, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 200...
|
|
Omeros Reports Phase 2 Data Showing Multiple Clinical Benefits in Patients Undergoing Arthroscopic Meniscectomy Surgery
Mar 31, 2010
|
12.1 KB |
|
| |
SEATTLE, March 31, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery(TM) product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clin...
|
|
Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31
Mar 15, 2010
|
8.6 KB |
|
| |
SEATTLE, March 15, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it will hold a conference call on Wednesday, March 31, 2010 to disc...
|
|
Omeros Licenses PDE7 Compounds for Parkinson's Disease Program
Mar 9, 2010
|
10.8 KB |
|
| |
SEATTLE, March 9, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license to compounds from Asubio Pharma Co., Ltd. for use in its PDE7 program, which is focused on the treatment of movement disorders. Omeros has demonstrated a previously unknown link between phosphodi...
|
|
Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
Jan 28, 2010
|
11.9 KB |
|
| |
SEATTLE, Jan 28, 2010 /PRNewswire via COMTEX News Network/ -- Omeros Corporation (Nasdaq: OMER) today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company's Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute ...
|
| Showing 1-13 of 13 |
Page: 1 |
|
|
